Results 41 to 50 of about 1,869 (168)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

, 2020
This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis ...
Scholand, Mary Beth, Glassberg, Marilyn K, Ogura, Takashi, Olsson, Julie, Swigris, Jeffrey J, Belloni, Paula, Howard, Monet, Maher, Toby M, Costabel, Ulrich, Kondoh, Yasuhiro, Neighbors, Margaret, Kardatzke, David, David Kardatzke, Toby M. Maher, Jeffrey J. Swigris, Margaret Neighbors, Ulrich Costabel, Monet Howard, Paula Belloni, Marilyn K. Glassberg, Mary Beth Scholand, Takashi Ogura, Julie Olsson, Yasuhiro Kondoh   +23 more
core   +1 more source

Lebrikizumab for atopic dermatitis. [PDF]

Aust Prescr
europepmc   +5 more sources

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).Methods Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response—IGA (0,1) or EASI 75 ...
Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras, Gaia Gallo, Marta Casillas, Yuxin Ding, Chenjia Xu, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard   +12 more
doaj   +1 more source

The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis

Frontiers in Immunology, 2022
BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang, Yan Zhang, Yan Zhang, Danrong Jing, Danrong Jing, Jun Cheng, Xiang Chen, Xiang Chen, Minxue Shen, Minxue Shen, Hong Liu, Hong Liu   +11 more
doaj   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Frontiers in Medicine, 2023
BackgroundAtopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging.
Bader Bashrahil, Bader Bashrahil, Ziyad Alzahrani, Ziyad Alzahrani, Sahal Samarkandy, Sahal Samarkandy, Abdullah Aman, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +9 more
doaj   +1 more source

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

Allergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva, Shraddha Sharma, Shireen Barakey, Ariel Wagner, Alice Keisar, Tali Bar‐on, Michal Itan, Ariel Munitz   +7 more
wiley   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Anthropometric patterns in children with moderate‐to‐severe atopic dermatitis: Cross‐sectional insights from the TREATkids cohort

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The relationship between atopic dermatitis (AD), weight, height, and body mass index (BMI) in children and adolescents and the impact of systemic treatments is controversial. We report the distribution of weight, height, and BMI in the German TREATkids cohort compared to a standardized German cohort (Kromeyer‐Hauschild)
Barbara Kind, Doreen Siegels, Hagen Ott, Susanne Abraham, René Sachse, Katharina Lönnecke, Inken Harder, Annice Heratizadeh, Katja Nemat, Christian Vogelberg, Dora Stölzl, Ines Gellhaus, Susanne Lau, Mehrak Yoosefi Moridani, Thomas Werfel, Stephan Weidinger, Jochen Schmitt, the TREATgermany study group   +17 more
wiley   +1 more source